Thanks hottod, lots of useful info as always. I was intrigued by your note that Stoke only have one drug in clinical trials, with a prevalence of 1:15,700. They have 4 others in pre-clinical. It's market cap is A$1.13B.
PYC seems to have a stronger pipeline, but valued at A$780m. Just interesting to see the differences.
Three things possibly holding back PYC at the moment:
- Being in Australia - biotech backwater (from a financial perspective)
- Being low on cash - cap raise or deal..?
- Lack of exposure to build the buy-side
Hoping the next 6 months changes the last 2...?
Thanks again.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.050(3.77%) |
Mkt cap ! $746.5M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.32 | $1.24 | $3.866M | 3.066M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15778 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 4989 | 7 |
View Market Depth
| Last trade - 14.17pm 11/08/2025 (20 minute delay) ? |
| PYC (ASX) Chart |